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Abstract
Background: Although modest improvements in the survival of patients with non-small cell lung
cancer (NSCLC) can be achieved with cisplatin-based chemotherapy (CT), its value is disputed in
the geriatric setting. In this study, we evaluate the feasibility of vinorelbine/cisplatin CT for elderly
NSCLC patients.
Methods: In this pilot phase I/II trial, all patients received CT with vinorelbine 25 mg/m2, on day 1
and 8, and cisplatin on day 1, in 28 days-cycles. After stratification for age (up to 75 years), younger
patients were sequentially allocated to moderate cisplatin doses (80 mg/m2 or 90 mg/m2), and older
patients were allocated to lower cisplatin doses (60 mg/m2 or 70 mg/m2). We recruited patients
aged over 70 years with newly diagnosed NSCLC, clinical stage III or IV, Karnofsky performance
status ≥ 70%, normal serum creatinine, peripheral neuropathy ≤ grade 1, and no prior cancer
therapy.
Results: Analysis was by intention to treat. Main toxicities (grade 3–4) was as follows: neutropenia,
20%; anemia, 11%; and thrombocytopenia, 2%; alopecia, 55%; fatigue, 11%; and peripheral
neurotoxicity, 2%. No grade 3–4 emesis or renal toxicity occurred. Global median time to
progression (TTP) and overall survival (OS) were 27.0 (95% CI: 10.1 to 43.7) weeks and 30.1 (95%
CI: 24.4 to 35.8) weeks; 1- and 2-year survival rates were 36.3% and 13.2%, respectively. Overall
response rate was 50.0% (95% CI: 35.4% to 64.5%), with 1 complete response; no difference on
response rate was noticed according to cisplatin dose. Median overall survival was 30.1 weeks, with
1- and 2-year survival rates of 36.3% and 13.2%, respectively.
Conclusion: Age does not preclude assessment on the role of cisplatin-vinorelbine CT for elderly
NSCLC patients with good performance status and adequate bodily functions.
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Background
Lung cancer is a disease with a great incidence in older
people. In Brazil, its incidence rate in male sex was
expected to reach 18.8:100.000 in 1999, and aged patients
may have accounted for 57% of all lung cancer deaths.
Unfortunately, up to two thirds will present at diagnosis
with advanced disease, requiring chemotherapy (CT) [1].
Vinorelbine, a semi synthetic vinca alkaloid, is a highly
active drug for NSCLC and its association with cisplatin is
worthwhile. European and Southwest Oncology Group
trials demonstrated that vinorelbine/cisplatin (VP) offer
therapeutic advantage over both drugs alone [2-4], previ-
ous cisplatin-based schedules [3]; comparing to taxane
combinations, VP is therapeutically equivalent to carbopl-
atin/paclitaxel [5] or carboplatin/docetaxel [6] but infe-
rior to cisplatin/docetaxel [6].
Although modest improvements in the survival of
patients with non-small cell lung cancer (NSCLC) can be
achieved with cisplatin-based CT [7], its value is disputed
in the geriatric context. The simultaneous presence of sev-
eral diseases and homeostenosis, an age-related physio-
logic process that change the way that the body handles
drugs, can shift therapeutic index, allowing harm out-
weigh any survival gain. On the other hand, underdiagno-
sis and undertreatment of lung cancer in the elderly is a
fact, often explained in terms of ageism in medical oncol-
ogy staff [8] and people's beliefs and fears about the dis-
ease and its treatment [8,9]. Whether we should treat or
not aged patients with cisplatin-based CT surely is an
unsolved issue. In this study, we evaluated the feasible-
ness and activity of vinorelbine/cisplatin CT for elderly
NSCLC patients.
Methods
This study enrolled patients older than 70 years with unre-
sectable locally advanced or metastatic NSCLC. Informed
consent was obtained from patients and their relatives, as
approved by the Institutional Ethical Committee. Inclu-
sion criteria: all patients had to have histologically con-
firmed NSCLC; Karnofsky performance status ≥ 70;
measurable disease; adequate bone marrow reserve (neu-
trophils ≥ 2 × 109/L and platelets ≥ 100 × 109/L), bilirubin
under 1.25 times upper normal value (UNV), aspartate
aminotransferase/alanine aminotransferase (AST/ALT)
under 2 times UNV, and renal function (creatinine level
under 120 µmol/L); no symptomatic brain metastasis; no
prior cancer therapy; no indication for palliative radiation
therapy; no previous or concomitant malignancy; and
adequate social support. Exclusion criteria were sympto-
matic peripheral neuropathy and comorbidity regarded as
an impediment for CT, such as renal disease, heart failure,
coronary heart disease, uncontrolled infection, and cogni-
tive impairment.
Baseline work up included a medical history and physical
examination; whole blood count (WBC) and biochemis-
try; chest x-ray; bone scintigraphy scan; chest, abdominal
and brain computed axial tomography scans; and electro-
cardiogram. Although pretreatment bone scan and brain
CAT scan are recommended only when signs or symp-
toms of disease are present, they were added here due to
Institutional Protocol Reviewers recommendation.
Treatment consisted of vinorelbine 25 mg/m2 on days 1
and 8, administered intravenously in bolus, followed by
intravenous cisplatin over 1 hour. CT was administered
every 4 weeks. Prophylactic anti-emetic drugs (intra
venous dexamethasone 20 mg and ondansetron 16 mg)
and fluid hydration (0.9% saline, 1 L/m2; and magnesium
sulfate, 20 mmol) was used to minimize renal toxicity.
Dexamethasone 4 mg PO BID plus metoclopramide 10
mg PO QID for 4 days was used to prevent delayed eme-
sis. Patients were time-sequentially assigned to one of two
groups, from lower to higher doses, according to age
strata. Study doses were defined based on previous reports
on renal tolerance of cisplatin in geriatric patients [10,11].
Age stratification was arbitrary. Those aged up to 75 years
received cisplatin 60 or 70 mg/m2 and those aged 70 to 75
received cisplatin 80 or 90 mg/m2. Assignation to high
dose groups (70 mg/m2 and 90 mg/m2) occurred after
evaluation of toxicity at inferior doses, evaluated accord-
ing to National Cancer Institute criteria. The protocol
required a minimum of 6 and a maximum of 18 patients
per group after the 1st cycle for safety analysis.
Chemotherapy doses were reduced for haematological,
neurological, hepatic and renal toxicities. Toxicity was
graded according to National Cancer Institute (NCI) com-
mon toxicity criteria guidelines. Changes in dosage were
based on WBC results obtained on day 1 of treatment; if
neutrophils were <1.5 × 109/L and platelets were <100 ×
109/L, treatment was delayed by 1 week. Treament on
days 8 had to be cancelled if neutrophil counts were <1.0
× 109/L and platelets were <100 × 109/L. If treatment
could not be given after a 2-week interval because of hae-
matological toxicity, it had to be discontinued and the
patient withdrawn from the study. Concomitant use of
hematopoietic growth factors were not allowed in the first
treatment cycle but were administered subsequently on
individual basis. Neurological toxicity above grade 2
resulted in suspension of treatment; ototoxicity grade 2 or
3 resulted in a 50% dose reduction of cisplatin.
The following dose modifications of vinorelbine were set
based on AST/ALT (aspartate aminotransferase/alanine
aminotransferase) and bilirubin values on day 1 or day 8
of treatment: if AST/ALT were between 5.1 and 20.0 ×
UNV or bilirubin was between 1.5 and 3.0 × UNV, dosing
was cancelled and the patient was reassessed 1 week later.BMC Cancer 2004, 4:69 http://www.biomedcentral.com/1471-2407/4/69
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If AST/ALT were >20.0 × UNV or bilirubin was >3.0 ×
UNV, vinorelbine was discontinued. If serum creatinine
was grade >1, the dose was delayed by 1 week and the test
repeated. After a 2-week delay, the patient was taken off
the study. WBC and biochemistry were also performed on
day + 14 of treatment.
We intended to administer a maximum of four CT cycles
followed by radiation therapy in responding patients with
stage III disease and six CT cycles in patients with wet IIIB
or stage IV disease. Notwithstanding radical radiation
therapy (RT) should deliver a total dose down to 66 Gy,
covering tumor site and regional lymph nodes, and palli-
ative therapy could use doses under to 45 Gy, the final
choice of dose, fractioning, irradiated volume, and ener-
gies of radiation was at the radiation oncologist's discre-
tion. Treatment interruption was allowed in case of
disease progression, severe adverse events, or patient
preference.
Chest x-ray was performed before each cycle, and CAT
scans every two cycle for response evaluation. Tumor
response was recorded according to World Health Organ-
ization criteria and measured by the same observer (JRP).
All responses had to be confirmed 3–4 weeks from initial
evaluation. We reported here the best response designa-
tion recorded from the start of treatment until disease pro-
gression. Patients stopping treatment with an
unconfirmed response, or only short stabilisation were
considered as inevaluable, unless the response or stabili-
sation was further confirmed in the absence of any treat-
ment. Patients were monitored for the first month off-
study then followed up every 2–3 months.
The dose intensity was calculated for both drugs by divid-
ing the actual dose delivered by the length of therapy.
Toxic death was defined as death occurring during the
chemotherapeutic phase (including four weeks after its
end) and due to drug toxicity. Early death was defined as
death within four weeks after a chemotherapy cycle with-
out severe toxicity and not related to the malignant dis-
ease. Response and survival were calculated by intention-
to-treat. Progression was defined in relation to the best
response obtained. The time to tumor progression lasted
from the first day of treatment to the date of the first
observation of progressive disease. Survival was defined as
the time elapsed from the beginning of CT until death or
last follow-up visit. Time-to-event analysis was performed
using the Kaplan-Meier product-limit estimator. All anal-
yses were carried out using a computer program (SPSS ver-
sion 8.0, Chicago, USA).
Results
Forty-four patients were recruited from July 1996 to June
1998; twenty-nine aged 70–75 year and fifteen older than
75 years. Cisplatin doses were as follows: in the older
cohort, seven patients received 60 mg/m2  and eight
received 70 mg/m2; in the former, fifteen patients received
80 mg/m2 and fourteen received 90 mg/m2. Patient char-
acteristics are given in Table 1. Most of the patients pre-
sented stage III disease (56.8%) and squamous cell
carcinoma (52.3%).
Table 1: Patient characteristics
Study Group Total
70 to 75 years > 75 years
80 mg/m2 (n = 15) 90 mg/m2 (n = 14) 60 mg/m2 (n = 7) 70 mg/m2 (n = 8) (n = 44)
Median age (range, in years) 73 (71 to 74) 73 (71 to 74) 79 (76 to 84) 77 (76 to 85) 74 (71 to 75)
Gender
Male 12 12 5 5 34 (77%)
F e m a l e 3223 1 0  ( 2 3 % )
Karnofsky performance status
7 0 8743 2 2  ( 5 0 % )
80 – 90 7 7 3 5 22 (50%)
Stage:
IIIA 5 1 - 2 8 (18%)
IIIB 5 8 3 1 17 (39%)
I V 5545 1 9  ( 4 3 % )
Histology:
Squamous cell carcinoma 9 5 2 7 23 (52%)
Adenocarcinoma 3 7 3 - 13 (30%)
O t h e r s 3221 8  ( 1 8 % )BMC Cancer 2004, 4:69 http://www.biomedcentral.com/1471-2407/4/69
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Treatment results are shown in Table 2. A total of 125 CT
cycles were administered and the median was 3 (range: 1
to 6). No difference was noticed on the dose intensity
achieved across the four groups (Kruskal-Wallis test, p =
0.13). Objective response could not be evaluated in six
patients due to treatment discontinuation before cycle 2:
early death (1), withdrawal of consent (2) and toxicity
(3). Twelve out of 25 patients with stage III disease
responded to CT and received radical radiation therapy
(median delivered dose: 50 Gy; range: 40 Gy to 66 Gy).
Fifteen patients (34.0%) received maximum allowed CT
cycles; excessive toxicity (n = 8), progressive disease (n =
3), progressive disease after initial response (n = 13), and
patient choice (n = 5) were reasons for protocol with-
drawal. At a median follow-up time of 77.2 weeks, six
patients were alive. Response rate (RR) was 50.0% (95%
CI: 35.4% to 64.5%), with 1 complete response. Global
median time to progression (TTP) and overall survival
(OS) were 27.0 (95% CI: 10.1 to 43.7) weeks and 30.1
(95% CI: 24.4 to 35.8) weeks; 1- and 2-year survival rates
were 36.3% and 13.2%, respectively. No significant differ-
ence was noticed in RR (p = 0.65), TTP (p = 0.62), and OS
(p = 0.44) across study groups. There was no difference
according to stage (III vs. IV) in RR (48% vs. 53%, p =
0.76), TTP (32.6 vs. 25.0 weeks, p = 0.73), or OS (31.7 vs.
28.6 weeks, p = 0.33). Likewise there was no difference
according to age groups (70–74 vs. ≥ 75 years) in RR (55%
vs. 40%, p = 0.34), TTP (31.7 vs. 28.6 weeks, p = 0.33), or
OS (30.1 vs. 31.7 weeks, p = 0.76).
Toxicity data are presented in Table 3. Hematological tox-
icity (grade 3–4) was as follows: neutropenia, 20%; ane-
mia, 11%; and thrombocytopenia, 2%. Common
nonhematologic grade 3–4 side effects were alopecia
(18%) and fatigue (11%); severe peripheral neurotoxicity
occurred in one patient; neither severe emesis nor renal
toxicity was noticed. At the highest cisplatin dose (90 mg/
m2) there were two early deaths and one toxic death due
to neutropenic sepsis. No case of febrile neutropenia was
noticed.
Discussion
Treatment of elderly NSCLC patients with cisplatin-based
regimens has been a less contentious matter nowadays
but toxicity remains a major issue. In our pilot study,
chemotherapy with cisplatin 70–80 mg/m2 on day 1 plus
vinorelbine 25 mg/m2 on days 1 and 8, repeated each 28
days per in the maximum four cycles, was feasible for eld-
erly NSCLC patients. Neurological and renal tolerance
was particularly good. At the time we developed the pro-
tocol, no quality-of-life instrument had been validated for
use in Brazil. Thus, a drawback in our study is the absence
of quality-of-life analysis, which precludes evaluation of
key dimensions in geriatric oncology.
Cisplatin induces a sensory neuropathy due to axonal
damage that is dependent on the total-dose and single-
dose intensity [12], and it is also time-dependent [13],
making histological lesions more common than clinical
toxicity. Although in this trial most patients received mod-
Table 2: Therapy results
Study Group Total
70 to 75 years > 75 years
80 mg/m2 (n = 15) 90 mg/m2 (n = 14) 60 mg/m2 (n = 7) 70 mg/m2 (n = 8) (n = 44)
Treatment administered
Chemotherapy cycles
No. 46 42 14 23 125
Median (range) 2 (1 to 4) 2 (1 to 5) 3 (1 to 5) 3 (1 to 6) 3 (1 to 6)
Vinorelbine (median, mg/m2/wk) 8.6 8.8 9.4 10.3 8.9
Cisplatin (median, mg/m2/wk) 13.6 15.9 11.2 14.4 14.5
Efficacy
Complete response - - - 1 1
Partial response 8 8 2 3 21
Stable disease 4 4 3 2 13
Progressive disease 2 1 - - 3
Not evaluated 1 1 2 2 6
Overall response rate (%) 53 57 29 50 50
Time to progression (median, in weeks) 25.0 23.0 15.7 18.4 27.0
Overall Survival
Median (weeks) 31.0 17.3 26.6 31.7 30.1
1-year (%) 40.0 35.7 28.5 37.5 36.3BMC Cancer 2004, 4:69 http://www.biomedcentral.com/1471-2407/4/69
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erate cisplatin doses, only one had grade 3 peripheral neu-
ropathy. Our data may reflect the low median of cycles
actually administered rather than inaccuracy of clinical
signs to evidence tissue lesion. Similarly, Ohe et al. [14]
delivered a median of three cycle of cisplatin-containing
CT and reported no case of severe neuropathy.
Cisplatin renal toxicity has been attributed to drug-pro-
tein interactions and the inactivation of specific brush
border enzymes, resulting in damage of the loops of
Henle, the distal tubules, and collecting ducts. Patients
aged above 70 or even 80 are regarded as susceptible to
cisplatin-induced renal damage as the younger counter-
parts [15,16] and current studies have reported a low inci-
dence of renal toxicity in elderly patients [14,17]. No case
of severe renal toxicity was noticed in our patients, as esti-
mated by serum creatinine and its clearance (Cockroft-
Gault method), but this finding may be artifactual due to
small sample sizes, selection bias, and low sensitivity of
estimated creatinine clearance to predict actual glomeru-
lar filtration rate (GFR) [18].
The observed response rate here was in the usually range
of NSCLC phase II trials, but the absence of external
review of radiological data and the widened confidence
intervals expected because of small sample sizes in each
group limit assertions that could otherwise be drawn. The
1-year survival rate (36%) was good but essentially equiv-
alent to the reported elsewhere [19] for vinorelbine alone
(32%) and inferior to the observed for weekly cisplatin-
docetaxel (64%) [14]. Nonetheless, survival figures
should be cautiously considered in this underpowered,
heterogeneous, non-randomized pilot study.
Vinorelbine is a cytotoxic agent that clearly has expanded
the therapeutic options for elderly NSCLC patients
[20,21]. The next logical step to improve therapeutic
indexes was to combine it with other active drugs.
Recently, relevant results emerged from European phase
III trials addressing the role of novel drugs in the treat-
ment of elderly NSCLC patients [19,22-25]. The Elderly
Lung Cancer Vinorelbine Italian Study (ELVIS) [19], inter-
rupted for slow recruitment, evidenced an improvement
of some lung cancer-related symptoms (pain and dysp-
nea), worsening of toxicity-related symptoms (cognitive
function, constipation, and peripheral neuropathy), and a
limited survival advantage (28 vs. 21 weeks) for single-
agent vinorelbine as compared to supportive care, a sur-
vival gain that resembles the benefit reported by meta-
analysis for nowadays considered substandard cisplatin-
based regimens in advanced NSCLC.
Although sequential administration of drugs is an attrac-
tive option for aged or frail patients, a setting where min-
imal treatment-related toxicity should be pursued,
research on the role of non-platinum combinations for
elderly NSCLC patients aroused attention. The Southern
Italy Cooperative Oncology Group (SICOG) evaluated
whether the association of vinorelbine and gemcitabine
would be better than vinorelbine alone. To date, final
results of this trial have not to come. Despite an article
focusing on the interim analysis of 120 patients (60 at
each group) claimed a survival advantage for the com-
bined arm [22], further intent-to-treat analysis including
18 patients more reached a less optimistic conclusion:
median survival in the combined and single-agent arms
were nearly the same (25 weeks and 23 weeks, respec-
tively) and both values were deemed comparable to the
observed in the supportive care arm of the ELVIS (21
Table 3: Patient tolerance
70 to 75 years > 75 years
80 mg/m2 90 mg/m2 60 mg/m2 70 mg/m2 Grade ≥ 3
34343434n %
Haematological
N e u t r o p h i l s 2312--1-9 2 0
H a e m o g l o b i n 2-2---1-5 1 1
P l a t e l e t s ------1-1 2
Clinical
Alopecia (grade 2) (3) (2) (1) (2) 8 18
F a t i g u e 1-2---1-4 9
N a u s e a  a n d  v o m i t i n g ---------
N e u r o s e n s o r y 1-------1 2
R e n a l ---------
I n f e c t i o n --1-----1 2
Early death - 2 - - 2 4
Toxic death - 1 - - 1 2BMC Cancer 2004, 4:69 http://www.biomedcentral.com/1471-2407/4/69
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weeks) [23]. Since that at least 152 patients was treated in
the SICOG trial [24], a definite report of mature survival
data is awaited. In addition, investigators of the Multi-
center Italian Lung Cancer in the Elderly Study (MILES)
[25] reported no survival benefit for the combination of
vinorelbine plus gemcitabine in comparison to single-
agent vinorelbine or gemcitabine in the treatment of eld-
erly NSCLC patients.
The question whether or not cisplatin-containing regi-
mens should be used to treat aged patients remains an
important, still open, issue. As observed for paclitaxel-car-
boplatin [26], gemcitabine-cisplatin [27], and docetaxel-
cisplatin [14] associations, the role of vinorelbine-cispla-
tin regimens deserve to be investigated. Until the outcome
of large clinical trials addressing this issue proves at least
the equivalence of newer drug associations to platinum-
based regimens, as seems to be true for the combination
of paclitaxel and gemcitabine [28], there are few reasons
to preclude the evaluation of current combined regimens
in the chemotherapy of elderly NSCLC patients with nor-
mal bodily functions and good performance status.
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